QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ELVN

QT80Enliven Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
45.10
+0.24+0.54%
OverviewShort InterestFilings
ELVNQT80Enliven Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
45.10+0.54%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own37.63%
Shs Outstand69.82M
Perf Week11.74%
Market Cap2.73BForward P/E-EPS next Y-2.40Insider Trans-0.52%Shs Float-Perf Month12.27%
Enterprise Value2.60BPEG-EPS next Q-0.42Inst Own-Short Float-Perf Quarter50.08%
Income-95900003.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y166.71%
Sales-P/B6.21EPS next Y-35.73%ROA-21.25%Short Interest-Perf YTD192.86%
Book/sh1.03P/C-EPS next 5Y-ROE-21.04%52W High48.53 -7.07%Perf Year106.88%
Cash/sh1.05P/FCF-EPS past 3/5Y-ROIC-25.52%52W Low14.79 204.94%Perf 3Y-
Dividend Est.-EV/EBITDA-26.38Sales past 3/5Y-Gross Margin0.00%Volatility6.15% 6.06%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM11.64%Oper. Margin0.00%ATR (14)3.07Perf 10Y-
Dividend Ex-Date-Quick Ratio40.32Sales Y/Y TTM-Profit Margin0.00%RSI (14)60.93Recom2.00
Dividend Gr. 3/5Y-Current Ratio40.32EPS Q/Q33.33%SMA2013.41%Beta1.11Target Price65.25
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA508.03%Rel Volume2.11Prev Close44.86
Employees62LT Debt/Eq-0.06EarningsAug 12SMA20059.75%Avg Volume1.16MPrice45.10
IPO DateMar 12, 2020Option/ShortYes / YesEPS/Sales Surpr.13.64% -Net Debt/EBITDA1.34Volume2,449,791Change0.54%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-08-26InitiatedStifelBuy$60
Jun-02-26ReiteratedMizuho Securities$39 → $62
May-12-26InitiatedGuggenheimBuy$80
May-08-26ReiteratedGoldman SachsBuy$59
Jun-16-25ReiteratedRobert W. Baird$40 → $52
Mar-21-25ReiteratedH.C. Wainwright$37 → $39
Nov-15-24ReiteratedRobert W. Baird$32 → $40
Sep-23-24ReiteratedMizuho Securities$34 → $39
Jun-10-24ReiteratedRobert W. Baird$32
Apr-09-24ReiteratedMizuho Securities$34
Latest News
Jun-15-26
Jun-15-2607:04PM
Enliven Therapeutics, Inc. (ELVN) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowSeekingAlpha
Jun-12-26
Jun-12-2601:31AM
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia - SlideshowSeekingAlpha
Jun-11-26
Jun-11-2602:42PM
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia TranscriptSeekingAlpha
02:42PM
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia TranscriptSeekingAlpha
11:44AM
Crude Oil Edges Higher; Driven Brands Posts Upbeat EarningsBenzinga
11:44AM
Crude Oil Edges Higher; Driven Brands Posts Upbeat EarningsBenzinga
10:10AM
Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On ThursdayBenzinga
10:10AM
Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On ThursdayBenzinga
08:57AM
Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 WeeksBenzinga
08:57AM
Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 WeeksBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other342419
Research and Development868165
Other Operating Expense-100
Operating Income-120-105-84
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-16-16-12
Net Income Before Taxes-104-89-72
Income Taxes
000
Consolidated Net Income-104-89-72
Net Income From Continuing Operations-104-89-72
Net Income-104-89-72
EPS (Recurring)-1.83-1.89-2.01
EPS (Basic, Before Extraordinaries)-1.83-1.89-2.01
EPS (Diluted)-1.83-1.89-2.01
EBITDA-103-88-71
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding574736
Market Capitalization878——
Operating Lease Expense
———
Insider Trading Volume
$49.47$46.22$42.98$39.74$36.49● Close Price0.00M3.25M6.51M9.76M13.01MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
ORBIMED ADVISORS LLC10% OwnerJun 15 '26Sale45.02281,40812,668,988245,728Jun 17 12:00 AM
Kunkel Lori AnneDirectorJun 05 '26Sale34.5410,000345,35151,884Jun 09 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMay 18 '26Sale39.795,000198,97225,000May 20 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMay 18 '26Option Exercise2.4810,00024,800126,268May 20 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERApr 17 '26Sale47.675,000238,35125,000Apr 21 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERApr 17 '26Option Exercise2.4810,00024,800131,268Apr 21 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMar 25 '26Sale35.1040,0001,404,02425,000Mar 27 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMar 25 '26Option Exercise2.4880,000198,400136,268Mar 27 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMar 17 '26Option Exercise2.4810,00024,800176,268Mar 19 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMar 17 '26Sale27.765,000138,80025,000Mar 19 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMar 10 '26Option Exercise2.4820,25850,240181,268Mar 11 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMar 10 '26Sale30.1910,129305,82725,000Mar 11 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMar 09 '26Option Exercise2.4859,742148,160191,397Mar 11 12:00 AM
Collins Helen LouiseCHIEF MEDICAL OFFICERMar 09 '26Sale30.0229,871896,81125,000Mar 11 12:00 AM
Hohl BenjaminCHIEF FINANCIAL OFFICERMar 06 '26Sale29.5810,000295,83951,000Mar 10 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR